thehansindia.com
Cure8 news brief
Why This Matters
The findings point to an immune-cell change that may happen before Crohn’s symptoms appear, which could help predict relapse or guide future therapies. That could eventually affect monitoring or new treatment strategies for people with IBD.
Who Should Pay Attention
Researchers studying IBD immune mechanisms, clinicians interested in biomarkers and disease prediction, and patients following IBD research and future treatment developments.
Study Snapshot
Story typeMainstream News
Evidence typeEarly laboratory research
Source depthFull source text
What To Know
Researchers at Mount Sinai report that gamma delta intraepithelial lymphocytes (gamma delta IELs) in the gut are reduced before clinical signs of Crohn’s-like ileitis in a mouse model and that loss of these cells may shift the balance toward pro-inflammatory responses.
The team suggests gamma delta IEL loss might serve as a predictive biomarker for relapse and that boosting these cells’ function could be explored as a therapeutic strategy.
This article summarizes a Science Immunology paper and highlights the potential role of gamma delta T cells in maintaining intestinal immune balance and preventing progression to chronic inflammation. It does not provide clinical recommendations or human trial results.
If you want the original study, look for the March 2025 Science Immunology article by the Mount Sinai group for full methods and data.
Keep In Mind
This report summarizes preclinical (mouse-model) research described in a scientific journal. Mouse findings don’t directly translate into new treatments or diagnostic tests for people yet. The news piece is a secondary summary; review the original Science Immunology paper for study design, limitations, and direct evidence supporting the claims.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationthehansindia.com
Indexed viaBing News
Source typeMainstream News
PublishedMar 23, 2025, 6:54 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Tissue-resident Granzyme K+ CD8 T cells fuel Crohn's - Bioengineer.org
If correct, the paper points to a previously underappreciated immune cell (GzmK+ tissue-resident CD8+ T cells) as a potential driver of Crohn’s inflammation — which could lead to new biomarkers or therapies that work...
Symptoms of ‘invisible disease’ that half a million Brits suffer as cases linked to scaly skin condition
The study suggests a possible link between psoriasis, leaky gut, and Crohn’s disease—topics that could help explain why some people with psoriasis report more gut problems. People with psoriasis or IBD may find the...
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
This press release reports phase 2 evidence that a new experimental antibody (duvakitug) showed clinical, endoscopic, and histologic improvements in both UC and Crohn’s disease, which could lead to a new treatment option...